trending Market Intelligence /marketintelligence/en/news-insights/trending/mthpw_s0jr5yaoylrkklwq2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Pfizer, Foundation Medicine to develop companion diagnostics

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Pfizer, Foundation Medicine to develop companion diagnostics

Pfizer Inc. entered a broad partnership with Foundation Medicine Inc. to develop and commercialize companion diagnostics for its oncology portfolio.

Through the partnership, Pfizer is expected to accelerate the discovery and development of precision oncology therapeutics by using Foundation Medicine's platform technology.

The companion diagnostics, or CDx, will be included in Foundation Medicine's FoundationOne CDx, a U.S. Food and Drug Administration-approved comprehensive genomic profiling assay for all solid tumors.

Further, Pfizer will have access to Foundation Medicine's data analytics platform, FoundationInsights, for its novel biomarker discovery and the optimization of its clinical trial design.

The company's oncology pipeline includes 10 FDA-approved oncology medicines for solid tumors and hematologic malignancies, as well as 17 assets in clinical development and 19 phase three studies.

Roche Holding AG is the majority owner of Foundation Medicine.